- call +1-201-465-4211
- email sales@mrinsights.biz
A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
Scope of the Report:
In the last several years, global market of Commercializing Biomarkers in Therapeutic and Diagnostic Applications developed rapidly, with an average growth rate of 8.49%. In 2015, the consumables revenue growth rate was about 8.5%, the services revenue growth rate was nearly 8.6%, and the consumables revenue growth rate was the highest among the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry.
North America is the largest consumer of Commercializing Biomarkers, with the sales market share nearly 42%.
The second place is Europe, following North America with the sales market share of 31%. Japan and China is also the important market, with the total sales marker share of 18.6%.
The worldwide market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications is expected to grow at a CAGR of roughly 6.1% over the next five years, will reach 24400 million US$ in 2024, from 17200 million US$ in 2019, according to a new study.
This report focuses on the Commercializing Biomarkers in Therapeutic and Diagnostic Applications in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Consumables
Services
Software
Market Segment by Applications, can be divided into
Oncology
Cardiology
Neurology
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Commercializing Biomarkers in Therapeutic and Diagnostic Applications product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, with price, sales, revenue and global market share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in 2017 and 2018.
Chapter 3, the Commercializing Biomarkers in Therapeutic and Diagnostic Applications competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Commercializing Biomarkers in Therapeutic and Diagnostic Applications breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Commercializing Biomarkers in Therapeutic and Diagnostic Applications market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Commercializing Biomarkers in Therapeutic and Diagnostic Applications sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
1.2 Market Analysis by Type
1.2.1 Consumables
1.2.2 Services
1.2.3 Software
1.3 Market Analysis by Applications
1.3.1 Oncology
1.3.2 Cardiology
1.3.3 Neurology
1.3.4 Other
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2014-2024)
1.4.1.2 Canada Market States and Outlook (2014-2024)
1.4.1.3 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2014-2024)
1.4.2.2 France Market States and Outlook (2014-2024)
1.4.2.3 UK Market States and Outlook (2014-2024)
1.4.2.4 Russia Market States and Outlook (2014-2024)
1.4.2.5 Italy Market States and Outlook (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2014-2024)
1.4.3.2 Japan Market States and Outlook (2014-2024)
1.4.3.3 Korea Market States and Outlook (2014-2024)
1.4.3.4 India Market States and Outlook (2014-2024)
1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2014-2024)
1.4.4.2 Egypt Market States and Outlook (2014-2024)
1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
1.4.4.4 South Africa Market States and Outlook (2014-2024)
1.4.4.5 Turkey Market States and Outlook (2014-2024)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Roche
2.1.1 Business Overview
2.1.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.2 Dako (Agilent Technologies)
2.2.1 Business Overview
2.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.3 Merck
2.3.1 Business Overview
2.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.4 BD
2.4.1 Business Overview
2.4.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.5 Abbott
2.5.1 Business Overview
2.5.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.6 Genesys Biolabs (20/20GeneSystems)
2.6.1 Business Overview
2.6.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.7 Affymetrix
2.7.1 Business Overview
2.7.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.8 Agendia
2.8.1 Business Overview
2.8.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.9 ALMAC
2.9.1 Business Overview
2.9.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.10 Arrayit
2.10.1 Business Overview
2.10.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.11 Biocartic
2.11.1 Business Overview
2.11.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.12 BG Medicine
2.12.1 Business Overview
2.12.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.13 KEGG EXPRESSION Database
2.13.1 Business Overview
2.13.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.14 Thermo Fisher
2.14.1 Business Overview
2.14.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.15 BGI
2.15.1 Business Overview
2.15.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Manufacturer (2017-2018)
3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Manufacturer (2017-2018)
3.3 Market Concentration Rate
3.3.1 Top 3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturer Market Share in 2018
3.3.2 Top 6 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturer Market Share in 2018
3.4 Market Competition Trend
4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Analysis by Regions
4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Market Share by Regions
4.1.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Regions (2014-2019)
4.1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Regions (2014-2019)
4.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
4.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
4.4 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
4.5 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
4.6 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
5 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Country
5.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Market Share by Country
5.1.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Country (2014-2019)
5.1.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Country (2014-2019)
5.2 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
5.3 Canada Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
5.4 Mexico Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
6 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Country
6.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Market Share by Country
6.1.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Country (2014-2019)
6.1.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Country (2014-2019)
6.2 Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
6.3 UK Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
6.4 France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
6.5 Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
6.6 Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
7 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Country
7.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Market Share by Country
7.1.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Country (2014-2019)
7.1.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Country (2014-2019)
7.2 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
7.3 Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
7.4 Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
7.5 India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
7.6 Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
8 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Country
8.1 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Market Share by Country
8.1.1 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Country (2014-2019)
8.1.2 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Country (2014-2019)
8.2 Brazil Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
8.3 Argentina Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
8.4 Colombia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
9 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Countries
9.1 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Market Share by Country
9.1.1 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Country (2014-2019)
9.1.2 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Country (2014-2019)
9.2 Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
9.3 Turkey Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
9.4 Egypt Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
9.5 Nigeria Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
9.6 South Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2014-2019)
10 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment by Type
10.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Market Share by Type (2014-2019)
10.1.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Type (2014-2019)
10.1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Type (2014-2019)
10.2 Consumables Sales Growth and Price
10.2.1 Global Consumables Sales Growth (2014-2019)
10.2.2 Global Consumables Price (2014-2019)
10.3 Services Sales Growth and Price
10.3.1 Global Services Sales Growth (2014-2019)
10.3.2 Global Services Price (2014-2019)
10.4 Software Sales Growth and Price
10.4.1 Global Software Sales Growth (2014-2019)
10.4.2 Global Software Price (2014-2019)
11 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment by Application
11.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Application (2014-2019)
11.2 Oncology Sales Growth (2014-2019)
11.3 Cardiology Sales Growth (2014-2019)
11.4 Neurology Sales Growth (2014-2019)
11.5 Other Sales Growth (2014-2019)
12 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Forecast (2019-2024)
12.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue and Growth Rate (2019-2024)
12.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Forecast by Regions (2019-2024)
12.2.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Forecast (2019-2024)
12.2.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Forecast (2019-2024)
12.2.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Forecast (2019-2024)
12.2.4 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Forecast (2019-2024)
12.2.5 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Forecast (2019-2024)
12.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Forecast by Type (2019-2024)
12.3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Forecast by Type (2019-2024)
12.3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share Forecast by Type (2019-2024)
12.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Forecast by Application (2019-2024)
12.4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Forecast by Application (2019-2024)
12.4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Picture
Table Product Specifications of Commercializing Biomarkers in Therapeutic and Diagnostic Application
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
